NASDAQ$SXTC

China SXT Pharmaceuticals Inc. · Q3 2018 earnings

Q3 2018 earnings · · Investor relations

Headline financials

Total Revenue

$5.59M

No prior period
EPS (adj)

$0.04

No prior period
Net Income

$1.01M

No prior period
Operating Income

$1.33M

No prior period
Gross Profit

$2.59M

No prior period
R&D Expense

$0.00

No prior period

Revenue & EPS history

China SXT · Revenue · Quarterly

$5.59M

Q3 2018

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 13 quarterly earnings reports

Historical avg

-5.7%

Avg return

Earnings day

-14.5%

Avg return

5 days after

-25.4%

Avg return

30 days after

23%

3 / 13 earnings

Positive

+20.4%

Q2 2020

Best reaction

-59.0%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-1.0%-1.9%-36.5%
Q4 2023-1.0%-100.0%-100.0%
Q2 2023-6.9%-4.9%-30.6%
Q4 2022+2.7%-13.4%-17.1%
Q2 2022-59.0%-62.8%-65.4%
Q4 2021-10.5%-9.7%-10.5%
Q2 2021+3.6%+0.8%+11.0%
Q4 2020-6.7%-1.2%-25.0%
Q2 2020+20.4%+15.6%+13.7%
Q4 2019-5.0%-4.8%-18.6%
Q4 2018-5.0%-4.8%-18.6%
Q4 2017-5.0%-4.8%-18.6%
Q2 2019-0.5%+3.6%-14.0%
Q3 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro